AbClon, Inc. engages in the development, manufacture and sale of antibody drugs. The firm was established to develop bio-synergy antibody therapeutics for overcoming intractable cancer. It offers antibodies and detection kits. The company was founded by Carl Erik Mathias Uhlén and Jong-Seo Lee on June 25, 2010 and is headquartered in Seoul, South Korea.